# Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma

> **NCT03562507** · PHASE2 · TERMINATED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 8 (actual)

## Conditions studied

- Renal Cell Carcinoma, Metastatic

## Interventions

- **DRUG:** ESK981
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03562507
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-11
- **Primary completion:** 2022-10-18
- **Final completion:** 2022-10-18
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Lack of patient population
- **Last updated:** 2024-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03562507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03562507, "Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03562507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*